Lithium in Acute and Maintenance Treatment of Bipolar Disorders



Fig. 12.1
Flow diagram of factors influencing the likelihood of adherence



The second component of the model suggests that, if symptoms occur, individuals will make some attempt to cope with them. Crucially, their choice of a particular coping strategy to cure or control the problem (e.g. taking lithium or using alcohol to contain the symptoms) will be influenced by whether that seems to be a logical step given their views (about the identity, cause, timeline, controllability and consequences of their symptoms) (Colom et al. 2005).

The individual will next appraise their coping strategy and come to a decision about how effective it has been. They will then continue to use this strategy or modify it accordingly. So a patient may refuse medication initially but later accept the need for lithium (or vice versa). Finally, it should be noted that individuals who perceive ‘coherence’ between (i) their experience of symptoms, (ii) the meaning they give to the symptoms (their interpretations) and (iii) the explanation offered to them by a significant other (which might be a clinician or a family member) are more likely to adhere to medication.

When reviewing the identity and consequences of the disorder, individuals will appraise the threat posed by their symptoms in terms of the severity of the illness and their susceptibility to relapses. If they see the threat as being real, they may be more inclined to accept the necessity of taking a mood stabilizer (see Clatworthy et al. 2009). Similarly, when considering whether the problem can be cured or controlled, adherence with lithium will be influenced by any concerns the individual has regarding taking medication (e.g. fear of ‘addiction’). Clatworthy et al. (2009) demonstrated that 30 % of 223 individuals with bipolar disorders had low levels of adherence and that adherence status was predicted by lower necessity-for-treatment beliefs (OR = 0.50; 95 % CI = 0.31–0.82) and more concerns about potential adverse effects (OR = 2.00; 95 % CI: 1.20–3.34). These predictors were independent of current mood state, illness and demographic characteristics, and, very importantly, it was noted that concerns about, rather than actual experience of, adverse events predicted lower levels of adherence. In addition, as an individual’s mental state improves, their beliefs about the necessity of taking lithium may diminish, whilst any concerns remain constant (or sometimes become more prominent in their thinking) – explaining why adherence status often changes over time.



12.7 Conclusions


Lithium remains an important treatment option for the acute and maintenance phases of bipolar disorder, but to optimize its benefits, clinicians need a clear framework for assessing and managing the risk of partial or total non-adherence in the short and long term. The relationship between necessity beliefs, concerns and adherence offers a target for clinical interventions to help patients to resolve their ambivalence about taking lithium. However, clinicians need a greater understanding of the origins of necessity beliefs and concerns about lithium. For example, research suggests that patients’ concerns may arise from ‘social representations’ (beliefs that are common among the general public about the dangers of treatments), so there is a need for further publicity about the benefits of lithium. Also, it appears that adherence behaviour is undermined by anticipated, rather than actual, experiences of adverse effects, so it is critical to teach patients how to manage specific side effects (and/or understand their significance) and not just to provide information about which side effects may occur. This helps to explain why basic education is less successful than more sophisticated psychoeducation or behavioural strategies in improving adherence (Tacchi and Scott 2005).


12.8 Summary


Following the first efficacy trial of lithium prophylaxis in recurrent mood disorders in 1967, lithium became the gold standard for bipolar disorders, but its use has declined over time as newer drugs have been labelled as mood stabilizers. This chapter has offered a selective review of studies, focusing on the usefulness of lithium in acute episodes of bipolar disorders and in maintenance treatment. The efficacy of lithium in acute episodes and as a prophylactic treatment has been tested against various antipsychotics in comparative, high-quality clinical trials. These trials have demonstrated the efficacy of lithium and confirmed that it is still the key mood stabilizer. Critically, we have considered the prevalence of partial or non-adherence with lithium and the reasons for individuals discontinuing a potentially beneficial treatment. We have described how using health beliefs and exploring patients’ views about the necessity for treatment, versus their concerns about medication, can predict and enhance adherence and offer a framework for intervention.


References



Baastrup PC, Schou M (1967) Lithium as a prophylactic agent. Its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry 16(2):162–172CrossRefPubMed


Baldessarini RJ, Leahy L, Arcona S, Gause D, Zhang W, Hennen J (2007) Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv 58(1):85–91CrossRefPubMed


Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG et al (1994) Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 271(12):918–924CrossRefPubMed


Cade JF (1949) Lithium salts in the treatment of psychotic excitement. Med J Aust 36(2):349–352


Cipriani A, Hawton K, Stockton S, Geddes JR (2013) Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 346:f3646CrossRefPubMed


Clatworthy J, Bowskill R, Parham R, Rank T, Scott J, Horne R (2009) Understanding medication non-adherence in bipolar disorders using a necessity-concerns framework. J Affect Disord 116(1–2):51–55CrossRefPubMed


Colom F, Vieta E, Sánchez-Moreno J, Martínez-Arán A, Reinares M, Goikolea JM, Scott J (2005) Stabilizing the stabilizer: group psychoeducation enhances the stability of serum lithium levels. Bipolar Disord 7(Suppl 5):32–36CrossRefPubMed


Duffy A, Horrocks J, Doucette S, Keown-Stoneman C, McCloskey S, Grof P (2014) The developmental trajectory of bipolar disorder. Br J Psychiatry 204(2):122–128. doi:10.​1192/​bjp.​bp.​113.​126706, Epub 2013 Nov 21CrossRefPubMed


Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM (2004) Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 161(2):217–222CrossRefPubMed


Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, Morriss R, Alder N, Juszczak E, BALANCE investigators and collaborators (2010) Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 375(9712):385–395CrossRefPubMed

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jun 17, 2017 | Posted by in PSYCHOLOGY | Comments Off on Lithium in Acute and Maintenance Treatment of Bipolar Disorders

Full access? Get Clinical Tree

Get Clinical Tree app for offline access